2023-507758-34-00
Completed
Phase 1
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.
Rose Pharma Inc.1 site in 1 country12 target enrollmentStarted: November 9, 2023Last updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Rose Pharma Inc.
- Enrollment
- 12
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CTC Clinical Trial Consultants AB, att. Anders Millerhovf
Scientific
Rose Pharma Inc.
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A phase 1, double-blind, placebo-controlled, randomized, single ascending dose and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of GHF-201 in healthy adult volunteers2024-519813-74-00CCDRD Cooperative Clinical Drug Research and Development AG, GHF-Golden Heart Flower Ltd.32
Completed
Phase 1
A three part randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and preliminary efficacy of an inhaled (nebulized) phage cocktail in healthy subjects and in patients with chronic colonization of the lung with Pseudomonas aeruginosa2023-507203-55-00Charite Research Organisation GmbH50
Recruiting
Phase 1
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.2024-512722-28-00Bioprojet Pharma161
Recruiting
Phase 1
Double-blind, randomized, placebo-controlled pilot clinical trial to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2 macrophages and fat-derived mesenchymal cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV)2023-507700-32-00Peaches Biotech S.L.50
Recruiting
Phase 1
Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult SmokersNCT07285122RAGE Bio90